Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hypertriglyceridemia Overview 9 Therapeutics Development 10 Pipeline Products for Hypertriglyceridemia - Overview 10 Pipeline Products for Hypertriglyceridemia - Comparative Analysis 11 Hypertriglyceridemia - Therapeutics under Development by Companies 12 Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes 14 Hypertriglyceridemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Hypertriglyceridemia - Products under Development by Companies 18 Hypertriglyceridemia - Products under Investigation by Universities/Institutes 19 Hypertriglyceridemia - Companies Involved in Therapeutics Development 20 Acasti Pharma Inc 20 Akcea Therapeutics Inc 21 Allergan Plc 22 Alnylam Pharmaceuticals Inc 23 Arisaph Pharmaceuticals Inc 24 AstraZeneca Plc 25 BASF SE 26 Cardax Inc 27 Catabasis Pharmaceuticals Inc 28 Celon Pharma SA 29 CymaBay Therapeutics Inc 30 Gemphire Therapeutics Inc 31 Jeil Pharmaceutical Co Ltd 32 Kyorin Pharmaceutical Co Ltd 33 LipimetiX Development Inc 34 Matinas BioPharma Holdings Inc 35 Sancilio & Company Inc 36 Zydus Cadila Healthcare Ltd 37 Hypertriglyceridemia - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 AEM-28 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AEM-2814 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ALN-AC3 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 ALN-ANG - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 ARI-3037MO - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 bezafibrate SR - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BioE-1115 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 BSN-272 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 CAT-2000 Series - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 CAT-2003 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 CDX-085 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 gemcabene calcium - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 icosabutate - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 IONIS-ANGPTL3LRx - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 IONIS-APOCIIILRX - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 LTPO-3FA - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 MAT-9001 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 MN-002 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 NKPL-66 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 omega-3-carboxylic acids - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 saroglitazar - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 SC-401 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 seladelpar - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Small Molecule for Hypertriglyceridaemia - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 volanesorsen sodium - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Hypertriglyceridemia - Dormant Projects 97 Hypertriglyceridemia - Discontinued Products 99 Hypertriglyceridemia - Product Development Milestones 100 Featured News & Press Releases 100 Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen 100 Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 101 Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions 102 May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen 103 Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia 103 Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims 104 Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA 104 Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 105 May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia 106 Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 107 Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial 107 Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 108 Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 108 Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 110 Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 110 Appendix 112 Methodology 112 Coverage 112 Secondary Research 112 Primary Research 112 Expert Panel Validation 112 Contact Us 112 Disclaimer 113

List of Tables Number of Products under Development for Hypertriglyceridemia, H2 2016 10 Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016 20 Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016 21 Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016 22 Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 23 Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 24 Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016 25 Hypertriglyceridemia - Pipeline by BASF SE, H2 2016 26 Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016 27 Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 28 Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016 29 Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016 30 Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016 31 Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 32 Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 33 Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016 34 Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016 35 Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016 36 Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 37 Assessment by Monotherapy Products, H2 2016 38 Number of Products by Stage and Target, H2 2016 40 Number of Products by Stage and Mechanism of Action, H2 2016 42 Number of Products by Stage and Route of Administration, H2 2016 44 Number of Products by Stage and Molecule Type, H2 2016 46 Hypertriglyceridemia - Dormant Projects, H2 2016 97 Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016 98 Hypertriglyceridemia - Discontinued Products, H2 2016 99 List of Figures Number of Products under Development for Hypertriglyceridemia, H2 2016 10 Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Products, H2 2016 17 Assessment by Monotherapy Products, H2 2016 38 Number of Products by Top 10 Targets, H2 2016 39 Number of Products by Stage and Top 10 Targets, H2 2016 39 Number of Products by Top 10 Mechanism of Actions, H2 2016 41 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41 Number of Products by Routes of Administration, H2 2016 43 Number of Products by Stage and Routes of Administration, H2 2016 43 Number of Products by Molecule Types, H2 2016 45 Number of Products by Stage and Molecule Types, H2 2016 45

Acasti Pharma Inc Akcea Therapeutics Inc Allergan Plc Alnylam Pharmaceuticals Inc Arisaph Pharmaceuticals Inc AstraZeneca Plc BASF SE Cardax Inc Catabasis Pharmaceuticals Inc Celon Pharma SA CymaBay Therapeutics Inc Gemphire Therapeutics Inc Jeil Pharmaceutical Co Ltd Kyorin Pharmaceutical Co Ltd LipimetiX Development Inc Matinas BioPharma Holdings Inc Sancilio & Company Inc Zydus Cadila Healthcare Ltd